SOURCE-BACKED ANSWER

What are the main evidence limits for PT-141 / Bremelanotide?

An approval for Vyleesi does not validate every product sold as PT-141 or use in populations outside the label.

DIRECT ANSWER

PT-141 / Bremelanotide evidence limits.

An approval for Vyleesi does not validate every product sold as PT-141 or use in populations outside the label.

Reviewed August 8, 2026. Each statement links to its evidence record, followed by the primary and official sources used for this answer.

01Main limitation

An approval for Vyleesi does not validate every product sold as PT-141 or use in populations outside the label.

Open evidence record
02Human evidence boundary

Two randomized phase 3 trials support branded bremelanotide for acquired, generalized HSDD in premenopausal women.

Open evidence record
03What the score does not mean

Evidence-depth scores do not establish effectiveness, safety, product quality, or personal suitability.

Open evidence record

PRIMARY & OFFICIAL SOURCES

Sources for this answer.

3 source records, with duplicates removed.